Home >> Bortezomib (PS-341)
Related Products
Bortezomib (PS-341) Proteasome Inhibitor

Catalog No.A2614
Size Price Stock Qty
10mM (in 1mL DMSO)
In stock
Bortezomib (PS-341, LDP-341, MLM341) Evaluation Sample
In stock
In stock
Bortezomib (PS-341, LDP-341, MLM341) 25mg
In stock
Bortezomib (PS-341, LDP-341, MLM341) 100mg
In stock
Bortezomib (PS-341, LDP-341, MLM341) 500mg
In stock

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors


Sample solution is provided at 25 µL, 10mM.

Product Citations

Quality Control

Chemical structure


Related Biological Data


Related Biological Data


Related Biological Data

After treatment with 25 nm bortezomib and L for 24h, the degradation of HK2 was reduced compared with the cells treated with L alone.
Method:Immunoblot assays; Cell Lines:Breast cancer cell; Concentrations:25nM; Incubation Time:24 h.

Related Biological Data


Related Biological Data


Related Biological Data


Related Biological Data


Biological Activity

Description Bortezomib (PS-341) is a potent inhibitor of 20S proteasome with Ki of 0.6 nM.
Targets 20S proteasome          
IC50 0.6 nM (Ki)          


Cell experiment [1]:

Cell lines

Canine malignant melanoma cell lines (CMM-1, CMM-2, ChMC, KMeC, LMeC, OMJ, OMS, OMK, and NML

Preparation method

The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.

Reaction Conditions

72h; IC50=3.5~5.6 nM (nine kinds of cells)


Bortezomib potently suppressed the growth in 21 drugs, while other compounds had no or minimal effect on cell growth. We thus focused on bortezomib and examined its growth inhibitory properties against nine canine malignant melanoma cell lines (CMM-1, CMM-2, ChMC, KMeC, LMeC, OMJ, OMS, OMK, and NML). Bortezomib inhibited the growth of all cell lines with calculated IC50 values of 3.5~5.6 nM.

Animal experiment [1]:

Animal models

Nude athymic mice

Dosage form

0.8 mg/kg; intravenous injection


The in vivo growth inhibitory activity of bortezomib against CMM-1 cells was evaluated using a xenograft mouse model. Bortezomib significantly suppressed the growth of tumours after Day 4 of treatment (P < 0.01, control vs. bortezomib). Tumours from the bortezomib-treated mice showed a significant decrease in mitotic index compared to controls (P<0.01). Similarly, the Ki67 index was significantly decreased in tumours excised from the bortezomib-treated mice when compared to controls (P < 0.01).

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.


[1] Ito K, Kobayashi M, Kuroki S, et al. The proteasome inhibitor bortezomib inhibits the growth of canine malignant melanoma cells in vitro and in vivo[J]. The Veterinary Journal, 2013, 198(3): 577-582.

Bortezomib (PS-341) Dilution Calculator

Concentration (start)
Volume (start)
Concentration (final)
Volume (final)


Bortezomib (PS-341) Molarity Calculator



Chemical Properties

Cas No. 179324-69-7 SDF Download SDF
Synonyms Bortezomib,PS-341,LDP-341,MLM341,MG-341,NSC-681239
Chemical Name [(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid
Canonical SMILES B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O
Formula C19H25BN4O4 M.Wt 384.24
Solubility >19.2mg/mL in DMSO Storage Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request

Research Update

1. Bortezomib-induced apoptosis in cultured pancreatic cancer cells is associated with ceramide production. Cancer Chemother Pharmacol. 2014 Jan;73(1):69-77. doi: 10.1007/s00280-013-2318-3. Epub 2013 Nov 5.
Bortezomib, a proteasome inhibitor with anti-pancreatic cancer activity, was assessed for its role in ceramide production.
2. Mitochondrial modulation decreases the bortezomib-resistance in multiple myeloma cells. Int J Cancer. 2013 Sep 15;133(6):1357-67. doi: 10.1002/ijc.28149. Epub 2013 Apr 4.
The resistance to bortezomib, a 20S proteasome inhibitor, in MM cell lines is correlated with mitochondrial activities and could be eliminated through regulation of mitochondrial genes.
4. Oncolytic vesicular stomatitis virus and bortezomib are antagonistic against myeloma cells in vitro but have additive anti-myeloma activity in vivo. Exp Hematol. 2013 Dec;41(12):1038-49. doi: 10.1016/j.exphem.2013.09.005. Epub 2013 Sep 22.
Instead of synergistically killing multiple myeloma cells, bortezomib inhibited the replication and spread of VSV in vitro through suppressing NF-KB activation resulting in diminished anti-tumor activity and increased VSV response. However, the combination of those two drugs exhibited synergistic effects in vivo to reduce tumor burden in two syngeneic, immunocompetent myeloma models.
5. A phase I study using bortezomib with weekly idarubicin for treatment of elderly patients with acute myeloid leukemia. Leuk Res. 2013 Nov;37(11):1502-8. doi: 10.1016/j.leukres.2013.09.003. Epub 2013 Sep 8.
The treatment of bortezomib combined with idarubicin was well tolerated in older AML patients with the maximum tolerated dose of 1.2 mg/m(2) and 10 mg/m(2) respectively.


Bortezomib (originally codenamed PS-341) is the first therapeutic proteasome inhibitor to the tested in humans. It is approved in the U.S. for treating relapsed multiple myeloma and mantle cell lymphoma. [1] The drug is an N-protected dipeptide and can be written as Pyz-Phe-boroLeu, which stands for pyrazinoic acid, phenylalanine and Leucine with a boronic acid instead of a carboxylic acid. Peptides are written N-terminus to C-terminus, and this convention is used here even though the "C-terminus" is a boronic acid instead of a carboxylic acid. While multiple mechanisms are likely to be involved, proteasome inhibition may prevent degradation of pro-apoptotic factors, permitting activation of programmed cell death in neoplastic cells dependent upon suppression of pro-apoptotic pathways. Recently, it was found that bortezomib caused a rapid and dramatic change in the levels of intracellular peptides that are produced by the proteasome. [2] Some intracellular peptides have been shown to be biologically active, and so the effect of bortezomib on the levels of intracellular peptides may contribute to the biological and/or side effects of the drug.

A potent (Ki = 0.6 nM), specific and reversible proteasome inhibitor. It inhibits cell proliferation of H460 cells (Human non-small cell lung cancer cell lines) with an IC₅₀ of 0.1 µM.

1. Takimoto CH, Calvo E. "Principles of Oncologic Pharmacotherapy" in Pazdur R, Wagman LD, Camphausen KA, Hoskins WJ (Eds) Cancer Management: A Multidisciplinary Approach. 11 ed. 2008.
2. Gelman JS, Sironi J, Berezniuk I, Dasgupta S, Castro LM, Gozzo FC, Ferro ES, Fricker LD (2013). "Alterations of the intracellular peptidome in response to the proteasome inhibitor bortezomib". In Gartel, Andrei L. PLoS One 8 (8): e53263.